LUNG CARCINOID WITH CUSHING'S SYNDROME: CONTROL OF SERUM ACTH AND CORTISOL LEVELS USING SMS 201–995 (SANDOSTATIN)
- 1 February 1988
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 28 (2) , 181-185
- https://doi.org/10.1111/j.1365-2265.1988.tb03654.x
Abstract
Two patients with Cushing's syndrome due to lung carcinoid tumours were given the long‐acting somatostatin analogue SMS 201–995 (Sandostatin). One received a single 50 μg dose which produced a 50% reduction in circulating ACTH levels within 4 h. The other has been maintained in clinical and biochemical remission for 10 weeks on 100 μg tid. This is the first report of the successful use of SMS 201–995 in carcinoid‐induced Cushing's syndrome, and suggests that this hormone analogue could be valuable in the long term medical management of such patients.This publication has 11 references indexed in Scilit:
- DIAGNOSIS AND MANAGEMENT OF ACTH‐DEPENDENT CUSHING'S SYNDROME: COMPARISON OF THE FEATURES IN ECTOPIC AND PITUITARY ACTH PRODUCTIONClinical Endocrinology, 1986
- Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1985
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- INHIBITION OF CHOLECYSTOKININ-PANCREOZYMIN RELEASE BY SOMATOSTATINThe Lancet, 1977
- Somatostatin Suppresses Secretin and Pancreatic Exocrine SecretionScience, 1975
- Long-term Infusion of Growth Hormone Release Inhibiting Hormone in Acromegaly: Effects on Pituitary and Pancreatic HormonesBMJ, 1974
- INHIBITION OF GASTRIN AND GASTRIC-ACID SECRETION BY GROWTH-HORMONE RELEASE-INHIBITING HORMONEThe Lancet, 1974
- INHIBITION OF INSULIN SECRETION BY SOMATOSTATINThe Lancet, 1973
- ACTION OF GROWTH-HORMONE-RELEASE INHIBITORY HORMONE IN HEALTHY MEN AND IN ACROMEGALYThe Lancet, 1973